Skip to main content
logo
BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
3.040
-0.270 (-8.16%)
At close: Oct 30, 2026, 4:00 PM EST
3.150
+0.110 (3.62%)
Pre-market: Nov 2, 2026, 8:12 AM EST

BriaCell Therapeutics Income Statement

Millions USD. Fiscal year is Aug - Jul.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
Selling, General & Admin
6.826.396.578.517.58
Research & Development
29.2420.8126.7614.767.71
Operating Expenses
36.0527.233.3323.2715.29
Operating Income
-36.05-27.2-33.33-23.27-15.29
Interest Expense
--0.04---0
Interest & Investment Income
-0.120.290.890.14
Earnings From Equity Investments
-0.26-0.22-0.11--
Currency Exchange Gain (Loss)
--0.02-0.03-0.04-0.03
Other Non Operating Income (Expenses)
0.90.7628.242.12-11.65
EBT Excluding Unusual Items
-35.42-26.61-4.93-20.3-26.84
Gain (Loss) on Sale of Investments
0.090.06---
Pretax Income
-35.33-26.56-4.93-20.3-26.84
Earnings From Continuing Operations
-35.33-26.56-4.93-20.3-26.84
Minority Interest in Earnings
0.420.240.14--
Net Income
-34.9-26.31-4.79-20.3-26.84
Net Income to Common
-34.9-26.31-4.79-20.3-26.84
Net Income Growth
-----
Shares Outstanding (Basic)
50000
Shares Outstanding (Diluted)
50000
Shares Change
1084.29%285.70%5.35%0.81%242.82%
EPS (Basic)
-6.97-62.19-43.68-194.97-259.83
EPS (Diluted)
-6.97-62.19-43.68-194.97-259.83
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jul '26 Jul '25 Jul '24 Jul '23 Jul '22
Free Cash Flow
-28.78-28.17-24.58-23.74-12.48
Free Cash Flow Per Share
-5.74-66.58-224.09-228.03-120.86
EBITDA
-35.93-27.1-33.25-23.26-15.27
D&A For EBITDA
0.120.110.080.020.02
EBIT
-36.05-27.2-33.33-23.27-15.29
SEC Filings: 10-K · 10-Q